Detalles de la búsqueda
1.
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Lancet Oncol
; 24(9): 1029-1041, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37657462
2.
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.
JAMA Netw Open
; 5(1): e2145446, 2022 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35084480
3.
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.
BioDrugs
; 36(1): 55-69, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35133617
4.
Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
JAMA Oncol
; 8(8): 1190-1194, 2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35653145
5.
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial.
BioDrugs
; 35(3): 337-350, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33826080
6.
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
Eur J Cancer
; 118: 169-177, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31377477
Resultados
1 -
6
de 6
1
Próxima >
>>